Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients

MELBOURNE, Australia, June 27, 2022 /PRNewswire/ — Avion Medical Skin Centres (AMSC) have entered into an arrangement with OncoBeta® GmbH to address non-melanoma pores and skin cancer (NMSC) patients in Australia, with the new, non-invasive ^{[1] [2]} Rhenium-SCT®. The very first AMSC area will open in Melbourne Victoria, to people in Q3 2022. Solutions will be supplied at a brand-new planet-course facility at the Melbourne Theranostics Innovation Centre (MTIC) in North Melbourne, which provides unparalleled entry to a mix of nuclear medicine technologies, therapeutics and innovative investigate.

AMSC is partnering with Munich-centered medical system and radiochemical business, OncoBeta, who are revolutionary epidermal radioisotope treatment and effectively released Rhenium-SCT – which is established to improve the way people imagine about NMSC treatment. The place regular treatment procedures normally entail surgery, which may perhaps have a chance of scarring or reduction of function, treatment with Rhenium-SCT employs a non-invasive ^{[1] [2]} superficial application of a paste that contains ß-emitting particles specifically to the lesion, which do away with cancer cells without the need to have for surgery. Treatment with Rhenium-SCT is painless ^{[1] [2]} and only involves a solitary session ^{[1] [2] [3] [4] [5]} in most situations.

Dr. Sam Vohra, founder of AMSC, suggests, “We are pretty very pleased to be opening this new treatment centre in the coronary heart of Melbourne’s oncology precinct and to provide this ground-breaking treatment to NMSC clients in Australia. The scientific proof has presently verified that Rhenium-SCT is an successful substitute to regular invasive solutions and can considerably enhance individual outcomes and high quality of life.”

Professor Rod Hicks, a pioneer of therapeutic nuclear medicine and founder of MTIC notes, “The use of externally used radioisotopes to effectively remedy pores and skin cancers goes back to the get started of the final century and the discovery of radium by Marie Curie. We have acknowledged for around a hundred many years that this solution operates but the Oncobeta tactic delivers this treatment into the 21^st century with large precision in the application of radiation only to the pores and skin most cancers, sparing standard pores and skin and without having the disfiguring surgery in some cases if not demanded.”

Shannon D. Brown III, CEO and Managing Director at OncoBeta, not too long ago visited Australia, and suggests, “We are focused on furnishing Rhenium-SCT in nations around the world with the highest will need, to offer as numerous people as feasible with effective scientific outcomes and positive effect on patients’ good quality of life. We are extremely enthusiastic for this partnership with Avion Medical Pores and skin Centres and continuing to assist doctors involved in the prognosis and treatment of NMSCs.”

Australia has the optimum incidence of NMSC in the world, and analysis rates are continuing to increase every single yr ^{[6] [7]}. NMSCs are most typical in places that are uncovered to the sunshine, including the confront, head and neck/shoulders ^[8]. Avion Medical Skin Centres gives NMSC sufferers a really successful ^[2] treatment solution that eliminates the fear and hesitation some clients could experience all over aesthetic results or loss of operate.

For far more info about Avion Medical Skin Centres be sure to stop by www.avionmedicalskin.com.au or for extra data about OncoBeta and Rhenium-SCT remember to go to: www.oncobeta.com.

Ahead-looking statements

This announcement includes forward-seeking statements that require dangers, uncertainties and other things, numerous of which are exterior of Avion Medical’s control, and which could trigger precise results to differ materially from the final results reviewed in the forward-seeking statements. Forward-hunting statements include statements concerning Avion Medical’s programs, aims, objectives, upcoming occasions, performance and/or other info that is not historic information and facts. All these types of forward-wanting statements are expressly experienced by these cautionary statements and any other cautionary statements which may possibly accompany the ahead-looking statements. Avion Medical undertakes no obligation to publicly update or revise forward-looking statements to mirror subsequent activities or situation just after the day built, apart from as expected by regulation.

For media enquiries, please get hold of by using email: push@showoffgroup.com

References

Sedda AF, et al. Clin Exper Dermatol. 200833:745–749.
Cipriani C, et al. J Dermatol Treat. 2020 DOI: 10.1080/09546634.2020.1793890.
Castellucci P, et al. Eur J Nucl Med Mol Imaging. 202148:1511–1521.
Cipriani C, et al. International Journal of Nuclear Medicine. 2017 July: 114–112.
Cipriani C, et al. Epidermal Radionuclide Therapy – Springer, 2014.
Lomas A, Leonardi-Bee J, Bath-Hextall F. 2012 Might166(5):1069-80. doi: 10.1111/j.1365-2133.2012.10830.x.
Diepgen TL & Mahler VM. Br J Dermatol. 2002146 (Suppl 61):1–6.
Cancer Council Australia. https://www.most cancers.org.au/most cancers-info/kinds-of-cancer/non-melanoma-pores and skin-most cancers (accessed June 2022).